Industry & Policy News

[Regeneron Pharmaceuticals, Inc.] Regeneron Pharmaceuticals, Inc. and Sanofi announced that the US FDA has approved Kevzara® for the treatment of polymyalgia rheumatica, an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.

[Carleton University] Carleton University researchers have received over $3 million from the Canadian Institutes for Health Research (CIHR). The funding will support projects developing solutions to the prevalence of diabetes, chronic pain, gut health disturbances and brain injuries.

[ScienceInsider] Researchers in the United Kingdom (UK) breathed a cautious sigh of relief yesterday after the government struck a deal with the European Union (EU) to fix post-Brexit disputes over issues including trade across Northern Ireland’s border.

[Evelo Biosciences, Inc. (GlobeNewswire, Inc.)] Evelo Biosciences, Inc. announced that its first extracellular vesicle product candidate, EDP2939, has progressed to dosing in a Phase II psoriasis clinical trial after completing a safety and tolerability review from a first cohort of human volunteers.

[Genascence Corporation (Cision US, Inc.)] Genascence Corporation announced it has been awarded $11.6 million over four years from the California Institute for Regenerative Medicine . The funding will be used to support Genascence's Phase 1b clinical trial of GNSC-001 in knee osteoarthritis, as well as phase-appropriate manufacturing activities.

[AstraZeneca] AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.